NASDAQ · Biotechnology

InflaRx N.V. (IFRX) Stock

$1.60 +4.58% NASDAQ: IFRX Healthcare

Valuation

MetricValue
Price$1.60
Market Cap$235.67M
P/E Ratio-3.14
P/B Ratio1.24
P/S Ratio-22374.81
EPS (TTM)$-0.64
52-Week High$2.95
52-Week Low$0.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-58.00%
ROA-23.46%
ROCE-24.94%
Gross Margin-246.46%
Operating Margin-1444.45%
Net Margin-1463.04%
Debt/Equity0.01
Current Ratio4.15

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-48.0M$-32.0M$-45.0M$-53.0M$-48.0M
Net Profit$-46.0M$-29.0M$-43.0M$-46.0M$-46.0M
EPS$-1.10$-0.61$-0.78$-0.78$-0.66
Op Margin——-70685.6%-31911.4%-164525.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$125.0M$102.0M$120.0M$76.0M$55.0M
Total Liabilities$20.0M$14.0M$18.0M$15.0M$14.0M
Cash$26.0M$16.0M$13.0M$18.0M$16.0M
Borrowings$1.0M$1.0M$1.0M$1.0M$1.0M

Latest News

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos GlobeNewswire · Jun 30, 2026 Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength? Zacks · Jun 26, 2026 What Do Analysts Say About InflaRx N.V. (IFRX)? Insider Monkey · Jun 10, 2026 Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now Insider Monkey · May 31, 2026 InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline MarketBeat · May 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-40.0M$-34.0M$-38.0M$-49.0M$-34.0M
Investing Cash Flow$-26.0M$19.0M$-18.0M$52.0M$3.0M
Financing Cash Flow$-3.0M$0$-3.0M$0$0
Net Cash Flow$0$-10.0M$-3.0M$6.0M$0
Free Cash Flow$-40.0M$-34.0M$-38.0M$-49.0M$-34.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.08
EV / EBITDA-2.07
FCF Yield-10.60%
Quick Ratio8.22
Interest Coverage-610.45
Return 1Y125.34%
Return 3Y-51.57%
Return 5Y-21.79%

Ownership

Insiders Held2.95%
Institutions Held30.29%
Institutions Float Held31.21%
Institutional HolderSharesReport Date
Suvretta Capital Management, LLC7,933,9102026-03-31
683 Capital Management LLC3,315,0002026-03-31
Bank of America Corporation1,975,0002026-03-31
Eversept Partners, LP1,758,5732026-03-31
Morgan Stanley1,175,5762026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARTVArtiva Biotherapeutics, Inc. $6.94 +2.06% -2.06 $339.30M 0.00%
ATYRaTyr Pharma, Inc. $0.25 -3.56% -0.46 $24.14M 0.00%
CNTBConnect Biopharma Holdings Limited $0.87 -1.21% -1.05 $54.78M 0.00%
CNTXContext Therapeutics Inc. $0.30 +1.74% -0.64 $27.95M 0.00%
IMAImageneBio, Inc. $4.24 -0.47% -0.87 $47.82M 0.00%

About InflaRx N.V.

InflaRx N.V. is led by CEO Niels C. Riedemann, employs 74 people, headquartered in DE, publicly traded since 2017.

InflaRx N.V. (IFRX) stock trades at $1.60 with a market capitalization of $235.67M. The stock is valued at a price-to-earnings (P/E) ratio of -3.14, price-to-book of 1.24, price-to-sales of -22374.81. Over the past 52 weeks the stock has ranged between $0.80 and $2.95, and currently trades 45.8% below its 52-week high.

On profitability, InflaRx N.V. generates a return on equity (ROE) of -58.00%, return on capital employed of -24.94%, an operating margin of -1444.45%, a net profit margin of -1463.04%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides